Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study ; volume:7 ; number:1 ; day:23 ; month:10 ; year:2007 ; pages:1-7 ; date:12.2007
BMC infectious diseases ; 7, Heft 1 (23.10.2007), 1-7, 12.2007
- Urheber
-
Veras, Maria Amelia SM
- Beteiligte Personen und Organisationen
-
Enanoria, Wayne TA
Castilho, Euclides A.
Reingold, Arthur L.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2334-7-119
- URN
-
urn:nbn:de:1111-2016030250073
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Veras, Maria Amelia SM
- Enanoria, Wayne TA
- Castilho, Euclides A.
- Reingold, Arthur L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
High Streptococcus pneumoniae colonization prevalence among HIV-infected Kenyan parents in the year before pneumococcal conjugate vaccine introduction
The effect of age on the response to the pneumococcal polysaccharide vaccine
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Long-term protection of hepatitis B vaccine in HIV-infected patients
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
High Streptococcus pneumoniae colonization prevalence among HIV-infected Kenyan parents in the year before pneumococcal conjugate vaccine introduction
The effect of age on the response to the pneumococcal polysaccharide vaccine
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Long-term protection of hepatitis B vaccine in HIV-infected patients
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
High Streptococcus pneumoniae colonization prevalence among HIV-infected Kenyan parents in the year before pneumococcal conjugate vaccine introduction
The effect of age on the response to the pneumococcal polysaccharide vaccine
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Adverse events of inactivated COVID-19 vaccine in HIV-infected adults